EAST WINDSOR, N.J.—Sabinsa’s Boswellia extract cream can be used to manage mild to moderate psoriasis through its anti-inflammatory effects. (Clinical Dertatology. 2014; 2(1) 17-24. doi:10.11138/cderm/2014.2.1.017)
The cream, made from Boswellia serrata Roxb extract standardized for 5 percent of 95 percent 3-O-Acetly-11-Keto Beta Boswellic Acid (AKBBA), was studied in an open label, multi-centered phase III clinical trial. Two hundred patients used the cream three times a day for 12 weeks.
“Our understanding of this ingredient, originating from one of the earliest compounds released by Sabinsa, called Boswellin®, is growing, and we want the world to know the positive research and the impact it has on human health," said Sabinsa founder Muhammed Majeed. “Such indications prevalent in Ayurvedic texts are now being proven by modern research, in terms of correctly standardizing, isolating the unique compound(s) and ultimately formulating safe and effective products."
The cream product is sold and marketed as a drug in India. Sabinsa holds several patents for this and other uses of Boswellia. Clinical trials in the United States are expected to begin in the near future[KK1] .